Considering that EGFRvIII expression in GBM often is accompanied with PTEN deficiency, which abates the efficacy of EGFRvIII inhibitors [37], combining an EGFRvIII inhibitor and an mTOR inhibitor might be a potential strategy for EGFR+PTEN− GBM. This evidence concerns the gene PTEN and glioblastoma.